View in EDS PDF Full Text

Chromosome 11q loss and MYCN amplification demonstrate synthetic lethality with checkpoint kinase 1 inhibition in neuroblastoma.

Saved in:
Bibliographic Details
Title: Chromosome 11q loss and MYCN amplification demonstrate synthetic lethality with checkpoint kinase 1 inhibition in neuroblastoma.
Authors: Keller KM; Department of Research, Princess Máxima Center for Pediatric Oncology, Utrecht, Netherlands., Eleveld TF; Department of Research, Princess Máxima Center for Pediatric Oncology, Utrecht, Netherlands., Schild L; Department of Research, Princess Máxima Center for Pediatric Oncology, Utrecht, Netherlands., van den Handel K; Department of Research, Princess Máxima Center for Pediatric Oncology, Utrecht, Netherlands., van den Boogaard M; Department of Research, Princess Máxima Center for Pediatric Oncology, Utrecht, Netherlands., Amo-Addae V; Department of Research, Princess Máxima Center for Pediatric Oncology, Utrecht, Netherlands., Eising S; Department of Research, Princess Máxima Center for Pediatric Oncology, Utrecht, Netherlands., Ober K; Department of Research, Princess Máxima Center for Pediatric Oncology, Utrecht, Netherlands., Koopmans B; Department of Research, Princess Máxima Center for Pediatric Oncology, Utrecht, Netherlands., Looijenga L; Department of Research, Princess Máxima Center for Pediatric Oncology, Utrecht, Netherlands., Tytgat GAM; Department of Research, Princess Máxima Center for Pediatric Oncology, Utrecht, Netherlands., Ylstra B; Department of Pathology, Cancer Center Amsterdam, Amsterdam UMC, Vrije Universiteit, Amsterdam, Netherlands., Molenaar JJ; Department of Research, Princess Máxima Center for Pediatric Oncology, Utrecht, Netherlands.; Department of Pharmaceutical Sciences, University Utrecht, Utrecht, Netherlands., Dolman MEM; Department of Research, Princess Máxima Center for Pediatric Oncology, Utrecht, Netherlands.; Children's Cancer Institute, Lowy Cancer Centre, UNSW Sydney, Kensington, NSW, Australia.; School of Women's and Children's Health, Faculty of Medicine, UNSW Sydney, Kensington, NSW, Australia., van Hooff SR; Department of Research, Princess Máxima Center for Pediatric Oncology, Utrecht, Netherlands.
Source: Frontiers in oncology [Front Oncol] 2022 Sep 27; Vol. 12, pp. 929123. Date of Electronic Publication: 2022 Sep 27 (Print Publication: 2022).
Publication Type: Journal Article
Journal Info: Publisher: Frontiers Research Foundation] Country of Publication: Switzerland NLM ID: 101568867 Publication Model: eCollection Cited Medium: Print ISSN: 2234-943X (Print) Linking ISSN: 2234943X NLM ISO Abbreviation: Front Oncol Subsets: PubMed not MEDLINE
Database: MEDLINE Ultimate
FullText Links:
  – Type: pdflink
Text:
  Availability: 0
Header DbId: mdl
DbLabel: MEDLINE Ultimate
An: 36237330
AccessLevel: 2
PubType: Academic Journal
PubTypeId: academicJournal
PreciseRelevancyScore: 0
IllustrationInfo
Items – Name: Title
  Label: Title
  Group: Ti
  Data: Chromosome 11q loss and MYCN amplification demonstrate synthetic lethality with checkpoint kinase 1 inhibition in neuroblastoma.
– Name: Author
  Label: Authors
  Group: Au
  Data: <searchLink fieldCode="AU" term="%22Keller+KM%22">Keller KM</searchLink>; Department of Research, Princess Máxima Center for Pediatric Oncology, Utrecht, Netherlands.<br /><searchLink fieldCode="AU" term="%22Eleveld+TF%22">Eleveld TF</searchLink>; Department of Research, Princess Máxima Center for Pediatric Oncology, Utrecht, Netherlands.<br /><searchLink fieldCode="AU" term="%22Schild+L%22">Schild L</searchLink>; Department of Research, Princess Máxima Center for Pediatric Oncology, Utrecht, Netherlands.<br /><searchLink fieldCode="AU" term="%22van+den+Handel+K%22">van den Handel K</searchLink>; Department of Research, Princess Máxima Center for Pediatric Oncology, Utrecht, Netherlands.<br /><searchLink fieldCode="AU" term="%22van+den+Boogaard+M%22">van den Boogaard M</searchLink>; Department of Research, Princess Máxima Center for Pediatric Oncology, Utrecht, Netherlands.<br /><searchLink fieldCode="AU" term="%22Amo-Addae+V%22">Amo-Addae V</searchLink>; Department of Research, Princess Máxima Center for Pediatric Oncology, Utrecht, Netherlands.<br /><searchLink fieldCode="AU" term="%22Eising+S%22">Eising S</searchLink>; Department of Research, Princess Máxima Center for Pediatric Oncology, Utrecht, Netherlands.<br /><searchLink fieldCode="AU" term="%22Ober+K%22">Ober K</searchLink>; Department of Research, Princess Máxima Center for Pediatric Oncology, Utrecht, Netherlands.<br /><searchLink fieldCode="AU" term="%22Koopmans+B%22">Koopmans B</searchLink>; Department of Research, Princess Máxima Center for Pediatric Oncology, Utrecht, Netherlands.<br /><searchLink fieldCode="AU" term="%22Looijenga+L%22">Looijenga L</searchLink>; Department of Research, Princess Máxima Center for Pediatric Oncology, Utrecht, Netherlands.<br /><searchLink fieldCode="AU" term="%22Tytgat+GAM%22">Tytgat GAM</searchLink>; Department of Research, Princess Máxima Center for Pediatric Oncology, Utrecht, Netherlands.<br /><searchLink fieldCode="AU" term="%22Ylstra+B%22">Ylstra B</searchLink>; Department of Pathology, Cancer Center Amsterdam, Amsterdam UMC, Vrije Universiteit, Amsterdam, Netherlands.<br /><searchLink fieldCode="AU" term="%22Molenaar+JJ%22">Molenaar JJ</searchLink>; Department of Research, Princess Máxima Center for Pediatric Oncology, Utrecht, Netherlands.; Department of Pharmaceutical Sciences, University Utrecht, Utrecht, Netherlands.<br /><searchLink fieldCode="AU" term="%22Dolman+MEM%22">Dolman MEM</searchLink>; Department of Research, Princess Máxima Center for Pediatric Oncology, Utrecht, Netherlands.; Children's Cancer Institute, Lowy Cancer Centre, UNSW Sydney, Kensington, NSW, Australia.; School of Women's and Children's Health, Faculty of Medicine, UNSW Sydney, Kensington, NSW, Australia.<br /><searchLink fieldCode="AU" term="%22van+Hooff+SR%22">van Hooff SR</searchLink>; Department of Research, Princess Máxima Center for Pediatric Oncology, Utrecht, Netherlands.
– Name: TitleSource
  Label: Source
  Group: Src
  Data: <searchLink fieldCode="JN" term="%22101568867%22">Frontiers in oncology</searchLink> [Front Oncol] 2022 Sep 27; Vol. 12, pp. 929123. <i>Date of Electronic Publication: </i>2022 Sep 27 (<i>Print Publication: </i>2022).
– Name: TypePub
  Label: Publication Type
  Group: TypPub
  Data: Journal Article
– Name: TitleSource
  Label: Journal Info
  Group: Src
  Data: <i>Publisher: </i><searchLink fieldCode="PB" term="%22Frontiers+Research+Foundation]%22">Frontiers Research Foundation] </searchLink><i>Country of Publication: </i>Switzerland <i>NLM ID: </i>101568867 <i>Publication Model: </i>eCollection <i>Cited Medium: </i>Print <i>ISSN: </i>2234-943X (Print) <i>Linking ISSN: </i><searchLink fieldCode="IS" term="%222234943X%22">2234943X </searchLink><i>NLM ISO Abbreviation: </i>Front Oncol <i>Subsets: </i>PubMed not MEDLINE
PLink https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=mdl&AN=36237330
RecordInfo BibRecord:
  BibEntity:
    Identifiers:
      – Type: doi
        Value: 10.3389/fonc.2022.929123
    Languages:
      – Code: eng
        Text: English
    PhysicalDescription:
      Pagination:
        StartPage: 929123
    Titles:
      – TitleFull: Chromosome 11q loss and MYCN amplification demonstrate synthetic lethality with checkpoint kinase 1 inhibition in neuroblastoma.
        Type: main
  BibRelationships:
    HasContributorRelationships:
      – PersonEntity:
          Name:
            NameFull: Keller KM
      – PersonEntity:
          Name:
            NameFull: Eleveld TF
      – PersonEntity:
          Name:
            NameFull: Schild L
      – PersonEntity:
          Name:
            NameFull: van den Handel K
      – PersonEntity:
          Name:
            NameFull: van den Boogaard M
      – PersonEntity:
          Name:
            NameFull: Amo-Addae V
      – PersonEntity:
          Name:
            NameFull: Eising S
      – PersonEntity:
          Name:
            NameFull: Ober K
      – PersonEntity:
          Name:
            NameFull: Koopmans B
      – PersonEntity:
          Name:
            NameFull: Looijenga L
      – PersonEntity:
          Name:
            NameFull: Tytgat GAM
      – PersonEntity:
          Name:
            NameFull: Ylstra B
      – PersonEntity:
          Name:
            NameFull: Molenaar JJ
      – PersonEntity:
          Name:
            NameFull: Dolman MEM
      – PersonEntity:
          Name:
            NameFull: van Hooff SR
    IsPartOfRelationships:
      – BibEntity:
          Dates:
            – D: 27
              M: 09
              Text: 2022 Sep 27
              Type: published
              Y: 2022
          Identifiers:
            – Type: issn-print
              Value: 2234-943X
          Numbering:
            – Type: volume
              Value: 12
          Titles:
            – TitleFull: Frontiers in oncology
              Type: main
ResultId 1